Paratek Pharmaceuticals Inc. company is working to create new forms of tetracycline that will be effective against newly resistant strains of bacteria and potentially treat diseases not associated with bacteria, including neurodegenerative and inflammatory conditions such as rheumatoid arthritis. It has synthesized more than 2,500 new tetracycline compounds and is sifting through each to find their possible applications. The company's Multiple Antibiotic Resistance Program (MAR) is looking at ways to genetically turn off bacteria's ability to survive, thereby preventing infection in the first place.

Flamel Technologies S.A. was founded in 1990 and is headquartered in Venissieux, France. Flamel Technologies S.A., a biopharmaceutical company, engages in the development of polymer-based drug delivery technologies for the improvement of medical applications in France. Its Medusa nanoparticulate technology is designed to deliver therapeutic proteins, peptides, and other large and small molecules injected subcutaneously. The company's Micropump technology is a multiparticulate technology for oral administration of small molecule drugs with applications in controlled-release, taste-masking, and bioavailability enhancement. Its products based on Medusa technology include Interferon-AlphaXL, an interferon-alpha 2b for the treatment of hepatitis C virus and various oncology applications; FT-105 basal insulin, a long-acting formulation of recombinant human insulin to insulin-dependent patients; and interleukin-2 for the treatment of renal cancer. The company's products based on Micropump technology comprise Coreg CR, an extended release formulation of carvedilol phosphate for use in the treatment of moderate to severe heart failure and left ventricular dysfunction following myocardial infarction, and hypertension; and Asacard162.5mg, a controlled release formulation of aspirin, which provide therapy for cardiovascular treatment. It has strategic alliances with GlaxoSmithKline, Merck Serono, Wyeth Pharmaceuticals, Pfizer, Corning S.A., Servier, and Corning Incorporated.

SCOLR Pharma, Inc. is a specialty pharmaceutical company, which through its Controlled Delivery Technology (CDT) platforms, develops prescription, over-the-counter (OTC) and nutritional products. The Company has developed multiple private-label controlled release nutritional products incorporating its CDT platforms that are sold by national retailers. The Company’s lead product candidate is a CDT-based controlled release formulation of ibuprofen, an analgesic used for the treatment of pain, fever and inflammation. It completed the pivotal phase III trial to evaluate the safety and efficacy of its 12 hour CDT 600 milligram controlled release ibuprofen for the OTC market. In addition, the Company submitted its first abbreviated new drug application (ANDA) for its 12-hour pseudoephedrine product on August 5, 2008.

Richter Gedeon was founded by Gedeon Richter in 1901. Richter Gedeon is less interested with Earth's tremors than it is with rumblings caused by human pain and ailments. Hungary's largest producer of pharmaceuticals, the company makes female hormones, ACE inhibitors, anti-anxiety drugs and OTC pain relievers, anti-inflammatories, and vitamin supplements. It specializes in gynecological, cardiovascular, and central nervous system treatments. Brands include Normodipine, Diroton, Panangin, Cavinton, and Mydeton. Richter has a presence in 30 countries; its products are distributed worldwide through its subsidiaries.

Arrow Therapeutics was founded in 1998; AstraZeneca acquired the firm in 2007. Arrow Therapeutics is a pharmaceutical product discovery company that is researching new anti-infective medicines. The company's top candidate is RSV604, an antiviral molecular program to combat respiratory syncytial virus (RSV), a leading cause of respiratory infections worldwide. This candidate is currently undergoing clinical trials and has been licensed to Novartis. Other leading programs include compounds developed to fight infectious dieseases such as Hepatitis C, herpes, and chicken pox.

Airborne, Inc. company makes a dietary supplement that contains herbal extracts, vitamins, electrolytes, amino acids, and antioxidants meant to boost the immune system. The effervescent tablets come in four flavors and a powdered formulation to be added to water. The products are sold nationwide in pharmacies, supermarkets, and mass merchant retailers such as Costco, CVS Caremark, Target, and Wal-Mart. Airborne was established in 1997 by former second-grade teacher Victoria Knight-McDowell. Private equity investors GF Capital Management holds a majority of the company.

Laboratorio Chile S.A. makes branded, generic, and OTC drugs, including treatments for respiratory and infectious diseases, as well as cardiovascular, neurological, pain management, and hormone therapy products. Laboratorio Chile also makes such consumer fare as sweetener Marco Sweet, nutritional supplement Esvit-C, and Freshmel antiseptic throat lozenges. The company markets its wares in over a dozen Latin American countries.

Achillion Pharmaceuticals, Inc. (Achillion) is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases. Within the anti-infective market, it focuses on the development of antivirals for the treatment of chronic hepatitis C and the development of antibacterials for the treatment of resistant bacterial infections. As of December 31, 2008, Achillion focused its efforts on advancing two late-stage preclinical candidates: ACH-1095, an NS4A antagonist for the treatment of chronic hepatitis C, being developed in collaboration with Gilead Sciences, Inc. (Gilead), and ACH-1625, a protease inhibitor also for the treatment of chronic hepatitis C. It has a pipeline of other product candidates, for which it is seeking appropriate collaborative partners. These product candidates include elvucitabine for the treatment of human immunodeficiency virus (HIV) infection and ACH-702 for the treatment of serious bacterial infections.

XTL Biopharmaceuticals Ltd. (XTL) is a biopharmaceutical company engaged in the acquisition and development of pharmaceutical products for the treatment of unmet medical needs, particularly the treatment of multiple myeloma (MM) and hepatitis C. The Company’s lead compound is Recombinant Erythropoietin (rHuEPO), a known compound that it is developing for the prolongation of MM patients' survival and improvement of their quality of life. MM is a severe and incurable malignant hematological cancer of plasma cells. XTL’s second program is the Diversity Oriented Synthesis program (DOS), which is focused on the development of pre-clinical hepatitis C small molecule inhibitors, which the Company had out-licensed to Presidio Pharmaceuticals, Inc. (Presidio), which is a private specialty pharmaceutical company on March 20, 2008.

Actavis U.S. is the US manufacturing and marketing unit of global generics firm Actavis. The company makes a wide variety of generic equivalents of both prescription and OTC drugs, in a number of forms, including liquids, tablets, creams, and suppositories. Among other consumer and specialty drugs, it makes acetaminophen, ibuprofen, and generic Rogaine. It has also launched generic versions of Pfizer's diabetes drug Glucotrol XL and GlaxoSmithKlein's Coreg tables for hypertension and myocardial infarction. Actavis U.S. has manufacturing facilities in Maryland, New Jersey, and North Carolina, from which it ships its own products and provides contract manufacturing services to third parties.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.